PMID: 6541449Aug 1, 1984

Disposition of [14C]aztreonam in rats, dogs, and monkeys

Antimicrobial Agents and Chemotherapy
K J KripalaniJ M Shaw


[14C]aztreonam was administered as single 25-mg/kg doses to dogs (intravenously and subcutaneously) and monkeys (intramuscularly and intravenously) and as single 50-mg/kg doses (intramuscularly and intravenously) to rats. In rats and dogs, radioactive moieties were excreted primarily in urine; in monkeys, they were excreted about equally in urine and feces. Unchanged aztreonam accounted for 77 to 86% of the radioactivity excreted in the urine of rats, dogs, and monkeys; SQ 26,992, the metabolite resulting from hydrolysis of the monobactam ring, accounted for 10 to 15%; and minor, unidentified metabolites accounted for the remainder. In rats with cannulated bile ducts, about 15% of an intramuscular dose was excreted in bile in 24 h; the bile contained a greater percentage of metabolites than that found in urine. In dogs, the apparent elimination half-life of aztreonam in serum was 0.7 h after intravenous administration. Aztreonam and SQ 26,992 accounted for most of the radioactivity in the sera of dogs and monkeys. Serum protein binding of aztreonam and its metabolites ranged from 28 to 35% in dogs and from 49 to 59% in monkeys. In the three species studied, aztreonam was most extensively metabolized in monkeys; SQ 26,992 and ot...Continue Reading


Oct 3, 1999·Antimicrobial Agents and Chemotherapy·E J ErnstJ P Wiener-Kronish


Jan 1, 1973·Analytical Biochemistry·L E Anderson, W O McClure
Sep 1, 1980·The Journal of Antimicrobial Chemotherapy·J ChamberlainJ McEwen
Sep 1, 1980·The Journal of Antimicrobial Chemotherapy·D S ReevesR P Bax
Sep 1, 1983·Antimicrobial Agents and Chemotherapy·E A SwabbA A Sugerman
Dec 1, 1981·The Journal of Antimicrobial Chemotherapy·H C Neu, P Labthavikul
Jun 11, 1981·Nature·R B SykesJ S Wells
Dec 1, 1981·The Journal of Antimicrobial Chemotherapy·E A SwabbA A Sugerman
Jun 1, 1982·Antimicrobial Agents and Chemotherapy·E A SwabbM Frantz

Related Concepts

Serum Proteins
Plasma Protein Binding Capacity
High Pressure Liquid Chromatography Procedure
Macaca fascicularis
Drug Stability
Metabolic Biotransformation

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Antimicrobial Agents and Chemotherapy
E A SwabbA A Sugerman
Antimicrobial Agents and Chemotherapy
S M SinghviB H Migdalof
Antimicrobial Agents and Chemotherapy
S M SinghviB H Migdalof
Antimicrobial Agents and Chemotherapy
P G JonesJ Pasternak
Antimicrobial Agents and Chemotherapy
H R StutmanE A Swabb
© 2020 Meta ULC. All rights reserved